At the heart of this innovative research lies the cellular structure known as the nuclear speckle, a membraneless organelle residing within the nucleus. These speckles are critical regulators of gene expression, orchestrating the production, folding, and degradation of proteins — a delicate balance called proteostasis. Lead investigator Bokai Zhu, Ph.D., assistant professor in the Department of Medicine and the Aging Institute at the University of Pittsburgh, highlights the newfound importance of nuclear speckles in neurodegeneration. “Our work indicates that the dysregulation of nuclear speckles plays a pivotal role in neuronal decline across various proteinopathies,” Zhu explains. This paradigm-shifting insight positions nuclear speckle modulation as an exciting target for therapeutic development.

Previous investigations by Zhu’s lab had uncovered that the morphology of nuclear speckles, particularly their sphericity, correlates with functional capacity. Speckles adopting a more spherical shape exhibited impaired proteostasis, whereas irregular shapes were associated with healthier protein handling. Armed with this observation, Zhu’s team hypothesized that pharmacological agents capable of altering speckle geometry towards less rounded configurations might restore proteostasis and mitigate pathological protein accumulation.

To test this hypothesis, the researchers embarked on an extensive screening of FDA-approved drugs, aiming to identify compounds that modify nuclear speckle sphericity. Remarkably, pyrvinium pamoate emerged as a potent candidate. Originally developed as an antihelminthic agent targeting pinworms, pyrvinium pamoate demonstrated a unique capacity to reduce nuclear speckle roundness and subsequently enhance cellular proteostasis. William Dion, Ph.D., a former graduate student and first author, recounts the excitement surrounding these findings: “Our data confirmed that modifying nuclear speckle shape with pyrvinium pamoate directly restored proteostasis in cellular models, validating our initial hypothesis.”

Building upon promising in vitro results, the team collaborated extensively with experts in tauopathies, notably Dr. Xu Chen at UC San Diego. Tauopathies are neurodegenerative disorders marked by the accumulation of misfolded tau protein, which leads to cognitive and motor impairments. In primary mouse neurons engineered to express human tau protein, treatment with pyrvinium pamoate resulted in approximately a 70% reduction in pathological tau levels — a striking outcome given the notoriously stubborn nature of tau aggregates. Zhu reflects, “The magnitude of tau clearance in these neurons was unexpected and underscored the potential of nuclear speckle modulation in disease-relevant models.”

Further work by graduate student Yuren Tao investigated human neurons harboring mutations linked to frontotemporal dementia, a devastating neurodegenerative condition. These mutated neurons exhibited abnormally shaped nuclear speckles and elevated tau accumulation. Administering low doses of pyrvinium pamoate successfully reinstated the irregular, functional speckle morphology, simultaneously driving a significant decrease in tau pathology. Importantly, these therapeutic effects were achieved without detectable cellular stress or toxicity, highlighting the drug’s safety profile in neuronal contexts.

The translational impact extended beyond mammalian systems, as demonstrated in Drosophila models of tauopathy. Locomotor deficits in these flies, measurable through their climbing ability, were effectively rescued by pyrvinium pamoate administration at both larval and adult stages. The restoration of motor function in these in vivo models solidifies the drug’s promise as a viable therapeutic candidate for neurodegenerative proteinopathies.

In a compelling extension of their research, Zhu’s team explored the applicability of their approach to retinal diseases marked by protein misfolding. Collaborating with Yuanyuan Chen, Ph.D., assistant professor of ophthalmology, the investigators utilized cultured mouse retinas to model retinitis pigmentosa. This inherited disorder arises due to misfolded rhodopsin proteins clogging rod photoreceptors, leading to progressive vision loss. Application of pyrvinium pamoate in this model demonstrated a capacity to alleviate protein aggregation, indicating that nuclear speckle rehabilitation may hold broad utility across diverse protein misfolding disorders.

To unravel the mechanistic underpinnings of pyrvinium pamoate’s action, the team employed advanced biophysical techniques, including optical tweezers that manipulate microscopic structures with laser precision. Conventional nuclear speckles exhibit high surface tension, maintaining their spherical form and mechanical rigidity. Treatment with pyrvinium pamoate markedly decreased the surface tension of nuclear speckles, rendering them malleable and capable of stretching and rupture. This biophysical alteration leads to a less spherical and more broadly distributed speckle structure within the nucleus.

Such morphological transformation has profound functional consequences. As Zhu explains, “Reducing the surface tension of nuclear speckles enhances their contact with chromatin, thereby facilitating transcriptional activation of genes involved in proteostasis.” Unlike traditional drugs that target discrete receptor proteins, pyrvinium pamoate exerts a global epigenetic influence by modulating the physical properties of nuclear organelles. This mechanism enables the coordinated upregulation of hundreds of proteostasis-regulating genes, which may account for its effectiveness in clearing diverse misfolded proteins.

The implications of this discovery are far-reaching. By targeting a previously underappreciated cellular structure and exploiting its biophysical properties, the study introduces an entirely new class of neuroprotective strategies. Zhu is optimistic about the clinical potential: “We are eager to advance this paradigm to human trials and assess whether rehabilitating nuclear speckles can translate into meaningful therapeutic benefits for patients suffering from devastating proteinopathies.”

In addition to the core research team led by Zhu and Chen, the study benefited from the contributions of scientists across multiple disciplines, including pharmacology, ophthalmology, and molecular neuroscience. This collaborative effort underscores the multifaceted nature of neurodegenerative disease research and the importance of integrated approaches in developing innovative therapies.

As the field moves forward, this work stands as a compelling testament to the power of re-envisioning fundamental cellular structures as therapeutic targets. The notion of “nuclear speckle rehabilitation” may soon become a central theme in neurodegenerative disease research, inspiring novel drug design strategies that harness biophysical modulation to restore neuronal health.

Subject of Research: Nuclear speckles and their role in proteostasis regulation to ameliorate proteinopathies

Article Title: SON-dependent nuclear speckle rehabilitation alleviates proteinopathies

Web References:

• https://www.nature.com/articles/s41467-025-62242-7
• http://dx.doi.org/10.1038/s41467-025-62242-7

Image Credits: Zhu lab

Keywords:
Cell biology, Cellular physiology, Nuclear localization, Molecular biology, Neuroscience, Cellular neuroscience, Molecular neuroscience, Alzheimer disease, Neurodegenerative diseases, Parkinsons disease, Neurological disorders, Diseases and disorders, Health and medicine

Parkinson’s disease, a progressive neurodegenerative disorder characterized primarily by motor dysfunction and dopaminergic neuron loss in the substantia nigra, remains a formidable challenge for translational neuroscience. While numerous rodent models have contributed foundational insights, the translational gap persists, underscoring the limitations of these models in fully recapitulating human pathophysiology. NHPs, sharing closer anatomical, genomic, and neurophysiological traits with humans, offer a superior model to simulate the complexity of PD, including its motor and non-motor symptomatology, disease progression, and response to pharmacological interventions.

Central to this advocacy is the recognition that advancing therapeutic strategies necessitates more than just model availability; it requires a comprehensive ecosystem integrating sophisticated tools, cutting-edge resources, and robust ethical frameworks. Investment in the development of novel NHP models that precisely mimic human neurodegenerative trajectories is critical. Such models must incorporate the heterogeneity of PD presentations, encompassing genetic variants, environmental factors, and age-related vulnerabilities, to provide a more holistic platform for investigating disease mechanisms and testing candidate therapies.

Furthermore, the ethical considerations surrounding NHP research command meticulous attention. The cognitive complexity and social behaviors of these primates impose a moral imperative to ensure their welfare and minimize suffering. This necessitates the establishment of stringent ethical standards that govern experimental design, housing conditions, and enrichment protocols. Equally important is transparency and active public engagement, fostering societal trust and understanding regarding the essential role of NHPs in addressing pressing neurological health challenges.

The implementation of an international research consortium dedicated to NHP-based neurodegenerative research emerges as a strategic solution to amplify collaborative efforts, optimize resource allocation, and standardize methodologies. Such a consortium would serve as a hub for consolidating expertise across neuroscience, primatology, genomics, and bioethics, facilitating the exchange of knowledge and accelerating discovery. Pooling data and biological resources internationally would mitigate duplication and foster rapid iteration of experimental paradigms aligned with clinical relevance.

Modern neuroimaging modalities and neurophysiological tools uniquely synergize with NHP research. Techniques such as positron emission tomography (PET), functional magnetic resonance imaging (fMRI), and in vivo electrophysiology in awake, behaving primates provide unprecedented resolution into disease mechanisms at cellular and circuit levels. Coupling these approaches with advanced molecular profiling and gene editing technologies further enhances the capacity of NHP models to interrogate pathogenesis and therapeutic impact with translational precision.

The ageing process itself is a complex, systemic phenomenon influenced by genetic, epigenetic, and environmental factors, culminating in increased susceptibility to neurodegenerative diseases like PD. NHPs naturally manifest ageing phenotypes that parallel those in humans, including cognitive decline, motor dysfunction, and neuropathological hallmarks, making them ideal subjects to dissect the interplay between ageing and neurodegeneration. This naturalistic aspect is challenging to emulate in short-lived rodent models, highlighting the irreplaceable value of primates in ageing research.

In addressing PD and ageing, the integration of multidisciplinary perspectives—from molecular biology and systems neuroscience to behavioral science and ethics—within the NHP research framework is paramount. This holistic approach ensures that findings extend beyond isolated observations to form cohesive mechanistic models, ultimately informing the development of targeted, patient-specific interventions.

Moreover, technological advances in gene editing, such as CRISPR/Cas9, have opened avenues to engineer precise genetic mutations associated with familial and sporadic forms of PD in NHPs. This capability allows for creating models that mirror the genetic underpinnings of human disease, enabling investigation into gene-environment interactions and the evaluation of gene therapy strategies within a physiologically relevant context.

Funding agencies and governmental bodies are called upon to prioritize resource allocation towards these endeavors, recognizing the pivotal role of NHP research in bridging experimental findings and clinical application. Long-term investments are imperative to sustain colony maintenance, develop infrastructure, and nurture training programs dedicated to NHP neuroscience, ensuring a robust pipeline of skilled investigators.

Public outreach and education are equally vital components of this proposed paradigm. Transparent communication about the scientific necessity, ethical safeguards, and prospective benefits of NHP research fosters informed societal discourse and supports continued engagement. By demystifying research practices and outcomes, the scientific community can galvanize public support and counteract potential misconceptions or opposition.

The envisioned international consortium would also facilitate the adoption and harmonization of standardized protocols, ensuring reproducibility and comparability of findings across laboratories and countries. This standardization is critical to build a cohesive body of evidence that can more effectively propel translational pipelines and regulatory approvals for novel therapeutics.

In the face of escalating global demographic shifts towards older populations, the urgency of confronting neurodegenerative disorders intensifies. NHP research, when strategically expanded and ethically conducted, offers an unparalleled platform to dissect disease complexity and accelerate therapeutic discovery, ultimately aiming to alleviate the immense societal and economic burdens imposed by PD and related ageing disorders.

The confluence of biological relevant modeling, cutting-edge technology, ethical stewardship, and international collaboration predicates a new era of neuroscience research. Harnessing the unique capabilities of non-human primates holds the promise to unlock the mechanistic enigmas of Parkinson’s disease and the ageing brain, translating into tangible clinical advances that preserve function and quality of life in aging populations worldwide.

Subject of Research: Neurodegenerative diseases, Parkinson’s disease, ageing, non-human primate models

Article Title: Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research.

Article References:
Bezard, E., Anderson, R.M., Badin, R.A. et al. Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research. npj Parkinsons Dis. 11, 227 (2025). https://doi.org/10.1038/s41531-025-01088-8

Image Credits: AI Generated